DK171684B1 - Dobbeltstrenget DNA-fragment, der koder for human-H2-præprorelaxin, human-H2-prorelaxin eller A- og B-kæderne i human-H2-relaxin, samt DNA-transfervektor, der indeholder en cDNA-deoxynukleotidsekvens, som svarer til et sådant DNA-fragment, celle transformeret med en sådan DNA-transfervektor, og fremgangsmåde til fremstilling af human-H2-prorelaxin eller -H2-relaxin ved dyrkning af en sådan celle - Google Patents

Dobbeltstrenget DNA-fragment, der koder for human-H2-præprorelaxin, human-H2-prorelaxin eller A- og B-kæderne i human-H2-relaxin, samt DNA-transfervektor, der indeholder en cDNA-deoxynukleotidsekvens, som svarer til et sådant DNA-fragment, celle transformeret med en sådan DNA-transfervektor, og fremgangsmåde til fremstilling af human-H2-prorelaxin eller -H2-relaxin ved dyrkning af en sådan celle Download PDF

Info

Publication number: DK171684B1
Authority: DK; Denmark
Prior art keywords: human; relaxin; chain; prorelaxin; dna fragment
Prior art date: 1982-12-13

Application number

DK573783A

Other languages

Danish (da)

English (en)

Other versions

DK573783A (da

DK573783D0 (da

Inventor

Peter John Hudson

Hugh David Niall

Geoffrey William Tregear

Original Assignee

Florey Howard Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-12-13

Filing date

1983-12-13

Publication date

1997-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3769889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK171684(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1983-12-13 Application filed by Florey Howard Inst filed Critical Florey Howard Inst

1983-12-13 Publication of DK573783D0 publication Critical patent/DK573783D0/da

1984-06-14 Publication of DK573783A publication Critical patent/DK573783A/da

1997-03-10 Application granted granted Critical

1997-03-10 Publication of DK171684B1 publication Critical patent/DK171684B1/da

Links

101001091088 Homo sapiens Prorelaxin H2 Proteins 0.000 title claims abstract description 24
102000049116 human RLN2 Human genes 0.000 title claims abstract description 24
108020004414 DNA Proteins 0.000 title claims description 49
239000012634 fragment Substances 0.000 title claims description 45
108090000103 Relaxin Proteins 0.000 title claims description 43
102000003743 Relaxin Human genes 0.000 title claims description 42
239000002299 complementary DNA Substances 0.000 title claims description 38
108010087851 prorelaxin Proteins 0.000 title claims description 29
238000012546 transfer Methods 0.000 title claims description 25
239000013598 vector Substances 0.000 title claims description 25
102000053602 DNA Human genes 0.000 title claims description 18
238000004519 manufacturing process Methods 0.000 title claims description 6
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 36
238000000034 method Methods 0.000 claims abstract description 35
108090000623 proteins and genes Proteins 0.000 claims description 57
150000001413 amino acids Chemical class 0.000 claims description 38
108020004705 Codon Proteins 0.000 claims description 28
108020004999 messenger RNA Proteins 0.000 claims description 27
239000002773 nucleotide Substances 0.000 claims description 22
125000003729 nucleotide group Chemical group 0.000 claims description 22
238000003776 cleavage reaction Methods 0.000 claims description 17
230000007017 scission Effects 0.000 claims description 17
102000004196 processed proteins & peptides Human genes 0.000 claims description 15
108091033380 Coding strand Proteins 0.000 claims description 9
230000000295 complement effect Effects 0.000 claims description 9
230000004071 biological effect Effects 0.000 claims description 6
102000004169 proteins and genes Human genes 0.000 claims description 4
230000001580 bacterial effect Effects 0.000 claims description 3
239000013612 plasmid Substances 0.000 claims description 2
241001515965 unidentified phage Species 0.000 claims description 2
OZBXOELNJBSJOA-UBHSHLNASA-N Asp-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N OZBXOELNJBSJOA-UBHSHLNASA-N 0.000 claims 3
QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 claims 3
CZCSUZMIRKFFFA-CIUDSAMLSA-N Leu-Ala-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O CZCSUZMIRKFFFA-CIUDSAMLSA-N 0.000 claims 3
IASQBRJGRVXNJI-YUMQZZPRSA-N Leu-Cys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)NCC(O)=O IASQBRJGRVXNJI-YUMQZZPRSA-N 0.000 claims 3
VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 claims 3
101500021084 Locusta migratoria 5 kDa peptide Proteins 0.000 claims 3
NQCJGQHHYZNUDK-DCAQKATOSA-N Lys-Arg-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CCCN=C(N)N NQCJGQHHYZNUDK-DCAQKATOSA-N 0.000 claims 3
CFVQPNSCQMKDPB-CIUDSAMLSA-N Lys-Cys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N CFVQPNSCQMKDPB-CIUDSAMLSA-N 0.000 claims 3
108010027338 isoleucylcysteine Proteins 0.000 claims 3
KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 claims 2
GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 claims 2
VNBNZUAPOYGRDB-ZDLURKLDSA-N Gly-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN)O VNBNZUAPOYGRDB-ZDLURKLDSA-N 0.000 claims 2
LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 claims 2
IJKNKFJZOJCKRR-GBALPHGKSA-N Thr-Trp-Ser Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 IJKNKFJZOJCKRR-GBALPHGKSA-N 0.000 claims 2
SDUBQHUJJWQTEU-XUXIUFHCSA-N Val-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C(C)C)N SDUBQHUJJWQTEU-XUXIUFHCSA-N 0.000 claims 2
229920001184 polypeptide Polymers 0.000 claims 2
IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 claims 2
YWWATNIVMOCSAV-UBHSHLNASA-N Ala-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YWWATNIVMOCSAV-UBHSHLNASA-N 0.000 claims 1
ZQHQTSONVIANQR-BQBZGAKWSA-N Cys-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N ZQHQTSONVIANQR-BQBZGAKWSA-N 0.000 claims 1
IRKLTAKLAFUTLA-KATARQTJSA-N Cys-Thr-Lys Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CCCCN)C(O)=O IRKLTAKLAFUTLA-KATARQTJSA-N 0.000 claims 1
CGAMSLMBYJHMDY-ONGXEEELSA-N His-Val-Gly Chemical compound CC(C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N CGAMSLMBYJHMDY-ONGXEEELSA-N 0.000 claims 1
FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 claims 1
FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 claims 1
GPAHWYRSHCKICP-GUBZILKMSA-N Met-Glu-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GPAHWYRSHCKICP-GUBZILKMSA-N 0.000 claims 1
NNFMANHDYSVNIO-DCAQKATOSA-N Ser-Lys-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NNFMANHDYSVNIO-DCAQKATOSA-N 0.000 claims 1
OJFFAQFRCVPHNN-JYBASQMISA-N Ser-Thr-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OJFFAQFRCVPHNN-JYBASQMISA-N 0.000 claims 1
108010013835 arginine glutamate Proteins 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
108010056582 methionylglutamic acid Proteins 0.000 claims 1
230000004048 modification Effects 0.000 abstract description 15
238000012986 modification Methods 0.000 abstract description 15
230000008569 process Effects 0.000 abstract description 6
239000000523 sample Substances 0.000 description 23
235000001014 amino acid Nutrition 0.000 description 22
229940024606 amino acid Drugs 0.000 description 22
BJRCFZKVYNDCJE-WBSNEMHCSA-N 99489-95-9 Chemical compound C([C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(=O)N2)[C@@H](C)CC)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC1=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1=CC=C(O)C=C1 BJRCFZKVYNDCJE-WBSNEMHCSA-N 0.000 description 17
108010075254 C-Peptide Proteins 0.000 description 15
241000700159 Rattus Species 0.000 description 14
108010090955 preprorelaxin Proteins 0.000 description 13
241000282898 Sus scrofa Species 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
241000972773 Aulopiformes Species 0.000 description 11
108091026890 Coding region Proteins 0.000 description 11
235000019515 salmon Nutrition 0.000 description 11
101150072436 H1 gene Proteins 0.000 description 10
230000014509 gene expression Effects 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
101150008307 H2 gene Proteins 0.000 description 9
230000000694 effects Effects 0.000 description 9
210000004246 corpus luteum Anatomy 0.000 description 7
230000002611 ovarian Effects 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
108010076504 Protein Sorting Signals Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
244000005700 microbiome Species 0.000 description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
238000012300 Sequence Analysis Methods 0.000 description 5
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
241000894007 species Species 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
210000001672 ovary Anatomy 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
101000976075 Homo sapiens Insulin Proteins 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 3
108020005187 Oligonucleotide Probes Proteins 0.000 description 3
108020005038 Terminator Codon Proteins 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
238000010367 cloning Methods 0.000 description 3
201000003511 ectopic pregnancy Diseases 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000002751 oligonucleotide probe Substances 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 2
241000251730 Chondrichthyes Species 0.000 description 2
SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
MUCIDQMDOYQYBR-IHRRRGAJSA-N Leu-Pro-His Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N MUCIDQMDOYQYBR-IHRRRGAJSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000013614 RNA sample Substances 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 2
-1 amino acid ester Chemical class 0.000 description 2
238000003556 assay Methods 0.000 description 2
238000000211 autoradiogram Methods 0.000 description 2
235000013405 beer Nutrition 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
230000029087 digestion Effects 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
108010066381 preproinsulin Proteins 0.000 description 2
238000012545 processing Methods 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000011451 sequencing strategy Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
239000004474 valine Substances 0.000 description 2
101150055869 25 gene Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
244000291564 Allium cepa Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
108050009160 DNA polymerase 1 Proteins 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
BTGMTHBOODBMHN-SUHMBNCMSA-N N-[3-[1-[[(3S)-2-hydroxy-5-oxooxolan-3-yl]carbamoyl]cyclopropyl]-2,4-dioxo-1-propan-2-ylpyrimidin-5-yl]-2-methyl-4-(naphthalen-2-ylamino)benzamide Chemical compound CC(C)n1cc(NC(=O)c2ccc(Nc3ccc4ccccc4c3)cc2C)c(=O)n(c1=O)C1(CC1)C(=O)N[C@H]1CC(=O)OC1O BTGMTHBOODBMHN-SUHMBNCMSA-N 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000251778 Squalus acanthias Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
108010060035 arginylproline Proteins 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
244000309466 calf Species 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000008602 contraction Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
238000007429 general method Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
108010057821 leucylproline Proteins 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
108010091748 peptide A Proteins 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
210000005059 placental tissue Anatomy 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
229940035893 uracil Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK573783A 1982-12-13 1983-12-13 Dobbeltstrenget DNA-fragment, der koder for human-H2-præprorelaxin, human-H2-prorelaxin eller A- og B-kæderne i human-H2-relaxin, samt DNA-transfervektor, der indeholder en cDNA-deoxynukleotidsekvens, som svarer til et sådant DNA-fragment, celle transformeret med en sådan DNA-transfervektor, og fremgangsmåde til fremstilling af human-H2-prorelaxin eller -H2-relaxin ved dyrkning af en sådan celle DK171684B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPF724782		1982-12-13
AUPF724782		1982-12-13

Publications (3)

Publication Number	Publication Date
DK573783D0 DK573783D0 (da)	1983-12-13
DK573783A DK573783A (da)	1984-06-14
DK171684B1 true DK171684B1 (da)	1997-03-10

Family

ID=3769889

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK573783A DK171684B1 (da)	1982-12-13	1983-12-13	Dobbeltstrenget DNA-fragment, der koder for human-H2-præprorelaxin, human-H2-prorelaxin eller A- og B-kæderne i human-H2-relaxin, samt DNA-transfervektor, der indeholder en cDNA-deoxynukleotidsekvens, som svarer til et sådant DNA-fragment, celle transformeret med en sådan DNA-transfervektor, og fremgangsmåde til fremstilling af human-H2-prorelaxin eller -H2-relaxin ved dyrkning af en sådan celle
DK143492A DK172012B1 (da)	1982-12-13	1992-11-30	Rekombinant human-H2-præprorelaxin, -prorelaxin og -relaxin samt polypeptid med relaxinaktivitet.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK143492A DK172012B1 (da)	1982-12-13	1992-11-30	Rekombinant human-H2-præprorelaxin, -prorelaxin og -relaxin samt polypeptid med relaxinaktivitet.

Country Status (14)

Country	Link
US (1)	US4758516A (es)
EP (2)	EP0303033B1 (es)
JP (3)	JP2545055B2 (es)
KR (1)	KR940002536B1 (es)
AT (2)	ATE62507T1 (es)
CA (1)	CA1220735A (es)
DE (1)	DE3382249D1 (es)
DK (2)	DK171684B1 (es)
ES (6)	ES8602133A1 (es)
HU (1)	HU197767B (es)
IE (1)	IE63902B1 (es)
IL (1)	IL70414A (es)
NZ (1)	NZ206534A (es)
ZA (1)	ZA839231B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL69469A (en) *	1982-08-12	1991-06-10	Florey Howard Inst	Polypeptide having human h1-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
US5179195A (en) *	1982-12-13	1993-01-12	Howard Florey Institute Of Experimental Physiology And Medicine	Human relaxin polypeptides
US4835251A (en) *	1986-06-23	1989-05-30	Genetech, Inc.	Method of chain combination
EP0260149A1 (en) *	1986-09-12	1988-03-16	Howard Florey Institute Of Experimental Physiology And Medicine	Human prorelaxin for therapeutic use
EP0407401B1 (en) *	1988-02-26	1993-04-21	Genentech, Inc.	Human relaxin formulation
JP2857684B2 (ja) *	1989-05-04	1999-02-17	ジェネンテク，インコーポレイテッド	ヒトリラキシンの単離のための方法および組成物
US5089419A (en) *	1989-08-07	1992-02-18	International Canine Genetics	Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals
US5166191A (en) *	1991-08-19	1992-11-24	Genentech, Inc.	Use of relaxin in cardiovascular therapy
US5478807A (en) *	1991-08-19	1995-12-26	Genentech, Inc.	Use of relaxin in the treatment of bradycardia
EP0611451A1 (en) *	1991-10-28	1994-08-24	The Board Of Regents, The University Of Texas System	A method for detecting a differentiation marker in normal and carcinoma cells and in biological samples and body fluid
US6348327B1 (en)	1991-12-06	2002-02-19	Genentech, Inc.	Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
WO1995000645A2 (en) *	1993-06-21	1995-01-05	Genentech, Inc.	Process for producing relaxin
US20050032683A1 (en) *	2000-10-04	2005-02-10	Amento Edward P.	Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US20040006205A1 (en) *	2001-04-03	2004-01-08	Li Li	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002324727A1 (en) *	2001-08-17	2003-03-03	The Board Of Trustees Of The Leland Stanford Junior University	Mammalian relaxin receptors
AU2003903124A0 (en) *	2003-06-20	2003-07-10	Mark Del Borgo	Analogues of heteromeric proteins
AU2005247332A1 (en) *	2004-04-30	2005-12-08	Corthera, Inc.	Methods and compositions for control of fetal growth via modulation of relaxin
US20060052304A1 (en) *	2004-09-02	2006-03-09	Bas Medical, Inc.	Method for remodeling bone and related sutures
EP2288367B1 (en) *	2008-05-16	2015-10-07	Corthera, Inc.	H2 relaxin for use in the treatment of premature cervical dilation
GR1006941B (el)	2009-06-01	2010-08-27	Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras),	Πεπτιδικη συνθεση (peptide synthesis)
US8389475B2 (en) *	2009-08-10	2013-03-05	The Board Of Trustees Of The Leland Stanford Junior University	Relaxin analogs
AU2011291943B2 (en)	2010-08-17	2015-01-22	Ambrx, Inc.	Modified relaxin polypeptides and their uses
MX2014000031A (es) *	2011-07-01	2014-07-09	Bayer Ip Gmbh	Polipeptidos de fusion de relaxina y usos de los mismos.
EP2630964A1 (en)	2012-02-22	2013-08-28	Immundiagnostik AG	Method and medicament for treating patients in risk of prediabetes and type-2 diabetes
US20160296632A1 (en)	2013-11-13	2016-10-13	Aequus Biopharma, Inc.	Engineered glycoproteins and uses thereof
EP2946788A1 (en)	2014-05-23	2015-11-25	Immundiagnostik AG	Method and composition for treating heart failure with preserved ejection fraction
JP7088911B2 (ja)	2016-05-18	2022-06-21	モデルナティエックスインコーポレイテッド	リラキシンをコードするポリヌクレオチド
KR102670432B1 (ko)	2017-02-08	2024-05-28	브리스톨-마이어스 스큅 컴퍼니	약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4468464A (en) *	1974-11-04	1984-08-28	The Board Of Trustees Of The Leland Stanford Junior University	Biologically functional molecular chimeras
GR70279B (es) *	1979-09-12	1982-09-03	Univ California
US4267101A (en) *	1980-02-01	1981-05-12	Serono Laboratories Inc.	Process for obtaining human relaxin from fetal membranes
EP0068375A3 (en) *	1981-06-22	1983-04-13	G.D. Searle & Co.	Recombinant dna techniques for the production of relaxin
IE55479B1 (en) *	1982-02-12	1990-09-26	Florey Howard Inst	Molecular cloning and characterization of the gene sequence coding for porcine relaxin
IL69469A (en) *	1982-08-12	1991-06-10	Florey Howard Inst	Polypeptide having human h1-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors

1983
- 1983-12-09 NZ NZ206534A patent/NZ206534A/en unknown
- 1983-12-09 IL IL70414A patent/IL70414A/xx not_active IP Right Cessation
- 1983-12-12 EP EP88110103A patent/EP0303033B1/en not_active Expired - Lifetime
- 1983-12-12 ES ES527964A patent/ES8602133A1/es not_active Expired
- 1983-12-12 CA CA000443049A patent/CA1220735A/en not_active Expired
- 1983-12-12 DE DE8383307553T patent/DE3382249D1/de not_active Expired - Lifetime
- 1983-12-12 IE IE290883A patent/IE63902B1/en not_active IP Right Cessation
- 1983-12-12 EP EP83307553A patent/EP0112149B1/en not_active Expired - Lifetime
- 1983-12-12 ZA ZA839231A patent/ZA839231B/xx unknown
- 1983-12-12 AT AT83307553T patent/ATE62507T1/de not_active IP Right Cessation
- 1983-12-12 AT AT88110103T patent/ATE90360T1/de not_active IP Right Cessation
- 1983-12-13 JP JP58233744A patent/JP2545055B2/ja not_active Expired - Lifetime
- 1983-12-13 US US06/560,790 patent/US4758516A/en not_active Expired - Lifetime
- 1983-12-13 HU HU834243A patent/HU197767B/hu unknown
- 1983-12-13 KR KR1019830005905A patent/KR940002536B1/ko not_active Expired - Lifetime
- 1983-12-13 DK DK573783A patent/DK171684B1/da not_active IP Right Cessation
1985
- 1985-06-17 ES ES544293A patent/ES8802249A1/es not_active Expired
1986
- 1986-02-17 ES ES552093A patent/ES8708016A1/es not_active Expired
- 1986-02-17 ES ES552095A patent/ES8801373A1/es not_active Expired
- 1986-02-17 ES ES552094A patent/ES8708015A1/es not_active Expired
1987
- 1987-05-11 ES ES557531A patent/ES8801675A1/es not_active Expired
1992
- 1992-11-30 DK DK143492A patent/DK172012B1/da not_active IP Right Cessation
1993
- 1993-03-22 JP JP5061747A patent/JP2677332B2/ja not_active Expired - Lifetime
1994
- 1994-10-26 JP JP6262254A patent/JP2891882B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPS59156284A (ja)	1984-09-05
EP0112149A3 (en)	1985-05-22
EP0303033B1 (en)	1993-06-09
ES8801373A1 (es)	1987-12-16
JP2545055B2 (ja)	1996-10-16
JPH06100585A (ja)	1994-04-12
EP0112149A2 (en)	1984-06-27
DK172012B1 (da)	1997-09-15
DK143492A (da)	1992-11-30
DE3382249D1 (de)	1991-05-16
ES527964A0 (es)	1985-11-16
KR940002536B1 (ko)	1994-03-25
ZA839231B (en)	1984-08-29
EP0303033A3 (en)	1989-10-25
ES552095A0 (es)	1987-12-16
DK573783A (da)	1984-06-14
EP0303033A2 (en)	1989-02-15
ES544293A0 (es)	1988-04-16
KR840007024A (ko)	1984-12-04
IE63902B1 (en)	1995-06-14
ES8708015A1 (es)	1987-09-01
JPH07173198A (ja)	1995-07-11
DK143492D0 (da)	1992-11-30
HU197767B (en)	1989-05-29
JP2677332B2 (ja)	1997-11-17
IE832908L (en)	1984-06-13
NZ206534A (en)	1988-05-30
US4758516A (en)	1988-07-19
ATE90360T1 (de)	1993-06-15
IL70414A (en)	1991-06-10
ES557531A0 (es)	1988-02-16
CA1220735A (en)	1987-04-21
ES552093A0 (es)	1987-09-01
ES8602133A1 (es)	1985-11-16
ES8801675A1 (es)	1988-02-16
EP0112149B1 (en)	1991-04-10
ES8802249A1 (es)	1988-04-16
ATE62507T1 (de)	1991-04-15
ES8708016A1 (es)	1987-09-01
ES552094A0 (es)	1987-09-01
IL70414A0 (en)	1984-03-30
DK573783D0 (da)	1983-12-13
JP2891882B2 (ja)	1999-05-17

Publication	Publication Date	Title
DK171684B1 (da)	1997-03-10	Dobbeltstrenget DNA-fragment, der koder for human-H2-præprorelaxin, human-H2-prorelaxin eller A- og B-kæderne i human-H2-relaxin, samt DNA-transfervektor, der indeholder en cDNA-deoxynukleotidsekvens, som svarer til et sådant DNA-fragment, celle transformeret med en sådan DNA-transfervektor, og fremgangsmåde til fremstilling af human-H2-prorelaxin eller -H2-relaxin ved dyrkning af en sådan celle
US5326694A (en)	1994-07-05	Process for synthesizing human H2-prorelaxin, human H2-relaxin and fusion proteins thereof
DK171827B1 (da)	1997-06-23	Dobbeltstrenget DNA-fragment, der koder for human-H1-præprorelaxin, human-H1-prorelaxin eller A- og B-kæderne i human-H1-relaxin, samt DNA-transfervektor, der indeholder en cDNA-deoxynukleotidsekvens, som svarer til et sådant DNA-fragment, celle transformeret med en sådan DNA-transfervektor, og fremgangsmåde til fremstilling af human-H1-prorelaxin eller -H1-relaxin ved dyrkning af en sådan celle
US5179195A (en)	1993-01-12	Human relaxin polypeptides
US5145962A (en)	1992-09-08	Human pro relaxin polypeptides
US5320953A (en)	1994-06-14	Process for synthesizing human H1-prorelaxin, H1-relaxin and fusion proteins thereof
AU643194B2 (en)	1993-11-11	Recombinant fish hormone proteins
EP0086649B1 (en)	1989-08-30	Molecular cloning and characterization of the gene sequence coding for porcine relaxin
US5053488A (en)	1991-10-01	Molecular cloning and characterization of a gene sequence coding for human relaxin
DE3382692T2 (de)	1993-09-16	Molekulare klonierung und charakterisierung einer weiteren gen-sequenz, die fuer menschliches relaxin kodiert.
IE930063L (en)	1984-06-13	Molecular cloning and characterisation of a further gene¹sequence coding for human relaxin
IE58669B1 (en)	1993-11-03	Molecular cloning and characterization of a gene sequence coding for human relaxin

Legal Events

Date	Code	Title	Description
2003-12-29	PUP	Patent expired